Azithromycin Tablets Solicitation

The solicitation SPE2D2-26-R-0008 for Azithromycin Tablets is a Lowest Price Technically Acceptable (LPTA) acquisition issued by the Defense Logistics Agency under the Department of Defense, targeting pharmaceutical suppliers to provide specified tablet formulations in unit-of-use packaging meeting stringent regulatory and technical standards. The contract encompasses five clinical line items for 250mg, 500mg, and 600mg azithromycin tablets in 6-count, 3-count, and 30-count bottles, with base quantities for each and four one-year option periods allowing for a potential five-year contract duration. Technical acceptability is strictly gated by compliance with current Good Manufacturing Practices, FDA licensing through an approved NDA, ANDA, or BLA, therapeutic equivalence “A” ratings, adherence to the Drug Supply Chain Security Act, and full disclosure of manufacturing facility locations and foreign ownership status. The packaging must be child-proof, cylindrical with minimum dimensional specifications, free of glass, and compatible with automated dispensing systems like Baxter ATC and OptiFill, while requiring GS1-128 or HIBCC barcode labeling at the unit level with NDC, lot number, and expiration date encoded to ANSI/ISO/IEC quality grade C or higher, avoiding barcode placement across perforations or in proximate pairs. Offerors must submit electronic proposals via the DIBBS portal in two volumes—one technical compliance package and one price proposal—with no page limits, but failure to address mandatory representations under FAR 52.204-19, DFARS 252.204-7018, and other referenced clauses results in disqualification. Past performance and technical compliance are evaluated as pass/fail gates before price is considered as the sole award criterion. Delivery is FOB destination to DLA and VA Prime Vendor distribution centers, with performance commencing 45 days after award and pricing effective 15 days after that. Contract payments are routed through Prime Vendor contractors, not directly by the government, and rights to payment cannot be assigned. The closing date has been amended to August 12, 2026, at 3:00 PM EDT, with proposals requiring valid UEI and CAGE codes and certification of small business or other socioeconomic status if applicable. The procurement excludes covered telecommunications equipment and requires full disclosure of country of origin for both active pharmaceutical ingredients and final products, with no tolerance for uncorrected FDA violations